deltatrials
Completed PHASE2 NCT00001155

Treatment of Wegener's Granulomatosis With Cyclophosphamide

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Vasculitis Wegener's Granulomatosis
Interventions cyclophosphamide
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Feb 29, 1976 Completion: Feb 28, 2002

This PHASE2 trial investigates Vasculitis and Wegener's Granulomatosis and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 1976 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Feb 1976

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States